Generics
Teva unveils first generic THIOLA (tiopronin) tablets for prevention of kidney stones in the US
18 May 2021 -

Teva Pharmaceuticals reported on Monday the availability of the first available prescription generic THIOLA (tiopronin) tablets for the prevention of kidney stones in the US.

In combination with high fluid intake, alkali and diet modification, the generic THIOLA (tiopronin) tablets are indicated for the prevention of cystine (kidney) stone formation in adults and paediatric patients nine years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.

With nearly 550 generic medicines available, the company has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US.

In addition, Teva Pharmaceuticals is the US affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA), a specialist in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.

Login
Username:

Password: